Trial · NCT01286493
Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination
NCT01286493, Not applicable, Completed, Queen Saovabha Memorial Institute; results first posted 2014-06-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination. Trials, record NCT01286493. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01286493
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination
- NCT number
- NCT01286493
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 33 participants, actual
- Lead sponsor
- Queen Saovabha Memorial Institute
- Conditions
- HIV, Rabies
- Interventions
- rabies vaccines on day 0 and 3
- First posted
- 2011-01-31
- Last updated
- 2015-11-18
- Results first posted
- 2014-06-04
- Limitations and caveats
- Small sample size heterogeneous characteristics of participants Use only CD4+ T lymphocyte counts as the only immunologic surrogate marker
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rabies Neutralizing Antibody Titers | Day 360 | Rabies Neutralizing Antibody titers(RNab)of HIV-infected patients who receive booster rabies vaccination would be measured by Rapid Fluorescent Focus Inhibition Test(RFFIT) method at day 0, 7, 14, 28, 90,180 and 360. RNab level above 0.5 IU/ml indicate acceptable protective antibody response. for 7 times in 1 year. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Rabies Neutralizing Antibody Titers | Day 360 | As preliminary study, the number of participants was estimated to be above 15 - 20 cases. | IU/ml | GEOMETRIC_MEAN |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rabies Neutralizing Antibody Titers | Rabies Vaccines on Day 0 and 3 | 8.48 | Full Range 0.50 to 218.10 | IU/ml |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Rabies Vaccines on Day 0 and 3 | 33 | |
| Overall Study | COMPLETED | Rabies Vaccines on Day 0 and 3 | 30 | |
| Overall Study | NOT COMPLETED | Rabies Vaccines on Day 0 and 3 | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Rabies Vaccines on Day 0 and 3 | ||
| Total, other adverse events | Rabies Vaccines on Day 0 and 3 | 0 | 33 |
| Total, serious adverse events | Rabies Vaccines on Day 0 and 3 | 0 | 33 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01286493
GET https://conductscience.org/api/trials/v1/NCT01286493/registered